Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 06.11.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ent Report on Form 8-K (this “Current Report).* Item 5.02 Departure of Directors or Certain Officers; Election of Direct |
| 27.08.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | connection with, the implementation of the Plan. Item 5.02 Departure of Directors or Certain Officers; Election of Direc |
| 22.04.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 28.01.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 07.11.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | t Report on Form 8-K (this "Current Report").* Item 5.02 Departure of Directors or Certain Officers; Election of Directo |
| 03.04.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
| 09.01.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Report on Form 8-K (this "Current Report"). Item 5.02 Departure of Directors or Certain Officers; Election of Directors; |
Stammdaten
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Unternehmen & Branche
| Name | Sight Sciences, Inc. |
|---|---|
| Ticker | SGHT |
| CIK | 0001531177 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Devices |
| SIC | 3841 · Surgical & Medical Instruments & Apparatus |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 234,4 Mio. USD |
| Beta | 2,49 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 77,363,000 | -38,426,000 | -0.74 | 115,300,000 | 63,942,000 |
| 2025-09-30 | 10-Q | 19,906,000 | -8,169,000 | -0.16 | 116,256,000 | 64,290,000 |
| 2025-06-30 | 10-Q | 19,564,000 | -11,941,000 | -0.23 | 121,971,000 | 70,012,000 |
| 2025-03-31 | 10-Q | 17,508,000 | -14,154,000 | -0.28 | 129,680,000 | 77,628,000 |
| 2024-12-31 | 10-K | 79,866,000 | -51,507,000 | -1.03 | 142,839,000 | 87,523,000 |
| 2024-09-30 | 10-Q | 20,157,000 | -11,066,000 | -0.22 | 143,597,000 | 94,957,000 |
| 2024-06-30 | 10-Q | 21,370,000 | -12,329,000 | -0.25 | 149,715,000 | 101,638,000 |
| 2024-03-31 | 10-Q | 19,265,000 | -16,266,000 | -0.33 | 155,560,000 | 109,209,000 |
| 2023-12-31 | 10-K | 81,056,000 | -55,547,000 | -1.14 | 166,651,000 | 120,215,000 |
| 2023-09-30 | 10-Q | 20,009,000 | -13,035,000 | -0.27 | 176,641,000 | 127,069,000 |
| 2023-06-30 | 10-Q | 23,471,000 | -14,754,000 | -0.30 | 185,289,000 | 136,131,000 |
| 2023-03-31 | 10-Q | 18,824,000 | -17,067,000 | -0.35 | 196,641,000 | 146,376,000 |
| 2022-12-31 | 10-K | 71,331,000 | -86,242,000 | -1.80 | 213,073,000 | 160,076,000 |
| 2022-09-30 | 10-Q | 18,677,000 | -22,229,000 | -0.46 | 225,234,000 | 172,939,000 |
| 2022-06-30 | 10-Q | 17,229,000 | -23,843,000 | -0.50 | 240,749,000 | 191,759,000 |
| 2022-03-31 | 10-Q | 14,881,000 | -23,263,000 | -0.49 | 258,590,000 | 211,911,000 |
| 2021-12-31 | 10-K | 48,956,000 | -62,960,000 | -2.36 | 280,186,000 | 232,107,000 |
| 2021-09-30 | 10-Q | 13,101,000 | -17,169,000 | -0.43 | 291,050,000 | -245,976,000 |
| 2021-06-30 | 10-Q | 12,535,000 | -17,615,000 | 52,510,000 | -117,289,000 | |
| 2021-03-31 | 10-Q | 8,635,000 | -12,240,000 | -100,801,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-06 | Rodberg James | Officer, Chief Financial Officer | Open Market Sale | -7,231 | 3.55 | -25,670.05 | -45,8% | |
| 2026-04-06 | HAYDEN JEREMY B. | Officer, Chief Legal Officer | Open Market Sale | -13,761 | 3.55 | -48,851.55 | -87,1% | |
| 2026-04-02 | Badawi David | Director, Officer, Chief Technology Officer | Open Market Sale | -8,168 | 3.48 | -28,424.64 | -50,7% | |
| 2026-04-02 | Bauerlein Alison | Officer, Chief Operating Officer | Open Market Sale | -25,874 | 3.48 | -90,041.52 | -160,6% | |
| 2026-01-06 | Bauerlein Alison | Officer, Chief Operating Officer | Open Market Sale | -9,647 | 7.48 | -72,159.56 | -128,7% | |
| 2026-01-05 | Bauerlein Alison | Officer, Chief Operating Officer | Open Market Sale | -10,896 | 7.82 | -85,206.72 | -152,0% | |
| 2025-10-02 | Bauerlein Alison | Officer, Chief Financial Officer | Open Market Sale | -19,948 | 3.30 | -65,828.40 | -117,4% | |
| 2025-07-02 | Link Matthew | Officer, Chief Commercial Officer | Open Market Sale | -4,889 | 4.10 | -20,035.12 | -35,7% | |
| 2025-07-02 | Bauerlein Alison | Officer, Chief Financial Officer | Open Market Sale | -19,260 | 4.10 | -78,927.48 | -140,8% | |
| 2025-05-19 | Bauerlein Alison | Officer, Chief Financial Officer | Open Market Sale | -13,066 | 3.48 | -45,430.48 | -81,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.